Accueil > Products > Anticorps > Anticorps pour Cytométrie en Flux

Anti-Human PCSK9 Antibody (SAA0158), PerCP (HV275147)

Fiche technique Partager le produit Copier les informations

Prix(USD) : $

Spécification :

50T
100T

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique

Aperçu

Numéro de catalogue	HV275147
Description	Anti-Human PCSK9 Antibody (SAA0158), PerCP [SAA0158] (HV275147) is a human monoclonal antibody detecting PCSK9 in FCM. Suitable for Human. Highlights ●Flow Cytometry — Validated for flow cytometry applications. ●Fluorescent Label — Direct conjugate for streamlined workflows.
Reactivité des espèces	Human
Applications	FCM
Espèce hôte	Human
Isotype	IgG2, lambda
ID de clone	SAA0158
Conjugaison	PerCP
Clonalité	Monoclonal
Cible	Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9
Niveau d'endotoxines	Please contact with the lab for this information.
Numéro d'accès	Q8NBP7
Forme	Liquid
Tampon de stockage	0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Store at 4°C for 12 months. Protect from light. Do not freeze.
Contexte	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ~74 kDa protein. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. PCSK9 is the therapeutic target of evolocumab (Repatha). 1. Poirier, S. et al. (2008) The Journal of biological chemistry 283, 2363-72. PMID: 18039658 2. Nassoury, N. et al. (2007) Traffic (Copenhagen, Denmark) 8, 718-32. PMID: 17461796 3. Fan, D. et al. (2008) Biochemistry 47, 1631-9. PMID: 18197702 4. Mayer, G. et al. (2008) The Journal of biological chemistry 283, 31791-801. PMID: 18799458 5. Chen, Y. et al. (2011) Biochemical and biophysical research communications 415, 515-8. PMID: 22074827 6. Jonas, MC. et al. (2008) EMBO reports 9, 916-22. PMID: 18660751
Note	For flow cytometric staining, the suggested use of this reagent is 0.5 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application. For research use only.

Images

Reférences

Fiche technique

Anti-Human PCSK9 Antibody (SAA0158), PerCP.pdf

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

=

Concentration

×

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

×

V₁ (Stock Vol.)

=

Working Solution

C₂ (Working Conc.)

×

V₂ (Working Vol.)

Recommandation

Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.

Courrier : support@abinScience.com

Liste des distributeurs

Anti-Human PCSK9 Antibody (SAA0158), PerCP